[Unilateral acral necrosis as a minor form of hand-foot syndrome. Patient with unilateral acral necrosis secondary to capecitabine therapy for metastatic breast cancer].
Hand-foot syndrome is a common toxic side-effect, particularly during chemotherapy, with an incidence of 6-64% overall and 10-24% for capecitabine (Xeloda) monotherapy. Consequently, differential diagnostic considerations should include hand-foot syndrome when acral skin lesions appear, particularly during capecitabine monotherapy. The dosage should be reduced or therapeutic regimen changed. We present a unique patient who while on capecitabine developed unilateral acral necrosis which should be classified as a minor form of hand-foot syndrome.
Sauter
C
C
Abteilung für Haut- und Geschlechtskrankheiten, Allergologie, Klinikum Stadt Hanau, Leimenstrasse 20, 63450 Hanau, Germany. Hautklinikum-Hanau@ndh.net
Saborowski
A
A
Ockenfels
H-M
HM
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000556:secondary; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004890:Erythema / Q000139:chemically induced*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006229:Hand Dermatoses / Q000139:chemically induced*; D006801:Humans; D009336:Necrosis; D012867:Skin / Q000473:pathology; D012883:Skin Ulcer / Q000139:chemically induced*; D013997:Time Factors; D014944:World Health Organization
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil